LLY Beats by 39% vs APP Craters 20%: The Sharpest Earnings Divergence of August 6

By Yogurt · 2026-08-07 · Earnings

Eli Lilly shattered Q2 estimates — $8.38 EPS vs $6.01 expected — as Zepbound and Mounjaro drove revenue to $22.97B, blowing past the $20.73B consensus. On the same day, AppLovin tanked 20% on a razor-thin revenue miss. The divergence tells you everything about how the market punishes and rewards right now.

Same Day. Opposite Outcomes. Maximum Insight.

On Wednesday August 6, two major companies reported earnings within hours of each other. One shattered every estimate by a margin so wide it moved markets. The other missed by less than 1% — and lost a fifth of its market cap by Thursday morning. The contrast between Eli Lilly ($LLY) and AppLovin ($APP) is the clearest possible illustration of how the stock market rewards and punishes companies right now.

Understanding what happened — and why the reaction was so asymmetric — tells you more about current market psychology than any macro data release.

Eli Lilly: The 39% Earnings Beat That Rewrote the Pharma Playbook

What the numbers said:

  • EPS: $8.38 adjusted vs. $6.01 expected — a 39% beat
  • Revenue: $22.97 billion vs. $20.73 billion expected — a $2.24B upside
  • Full-year revenue guidance raised to $85–87B (from $82–85B)
  • Key Products revenue grew 121% year-over-year
  • GLP-1 market share: 60.9% of the entire U.S. obesity and diabetes drug market

These are not normal numbers. Beating EPS by 39% at Lilly's scale — a company approaching a $1.1 trillion market cap — is a statistical anomaly. For context, a typical large-cap earnings beat is 3–7%. Lilly came in nearly six times that.

Zepbound + Mounjaro: The GLP-1 Engine That Keeps Accelerating

The Zepbound and Mounjaro franchise is not slowing down. These two drugs — both based on Lilly's tirzepatide molecule — drove the quarter. Combined, they hold 60.9% of the entire U.S. obesity and diabetes drug market, with Novo Nordisk losing ground. For investors who have watched this space closely, that market share consolidation is the most important data point in the release.

CEO Dave Ricks put it simply on CNBC's Squawk Box: "It's hard to think of a time that we've been in a better position than this." That's not a boast — it's a reflection of the supply/demand dynamics. Lilly has been manufacturing aggressively, and the product is now widely available in ways it wasn't 12 months ago. The removal of the supply bottleneck has allowed the commercial engine to run at full speed.

The raised guidance tells the full story: $85–87 billion in full-year revenue, up from $82–85B. That midpoint raise of $2.5 billion in a single quarter is a signal that management is not just beating — they're building conviction about the second half.

The M&A Machine: Lilly Is Redeploying Its Cash at Scale

There's a second story inside the LLY print: the company's acquisition strategy. Fueled by its obesity drug windfall, Lilly has been on a buying spree unlike anything in recent pharma history. This quarter alone, the company struck a deal to acquire a psychedelics drugmaker (July), and previously announced the acquisition of three vaccine makers (May).

This is strategic portfolio building at speed. Lilly is using GLP-1 cash flows to buy optionality in emerging drug categories — psychedelics (for depression and PTSD), vaccines, and several oncology platforms. The EPS guidance was technically offset by $3.03/share in acquisition charges, but management raised the underlying profit guidance by $2.78/share at the midpoint. The deals are accretive to the long-term story even as they create short-term GAAP noise.

AppLovin: The 1% Miss That Cost 20%

Now for the counterpoint.

What the numbers said:

  • Revenue: $1.92B vs $1.94B expected — a miss of less than 1%
  • EPS: $3.76 vs $3.75 expected — technically a beat
  • Adjusted EBITDA margin: 84% — still exceptional
  • Revenue growth: +52.8% year-over-year
  • Q3 guidance: $2.07B — came in 0.6% below consensus
  • Stock reaction: -20% to -21% the following day

On pure fundamental metrics, this is still a high-quality business. Growing 53% year-over-year with 84% EBITDA margins is an extraordinary combination. In most market environments, these results would be celebrated. But AppLovin is not priced for "extraordinary" — it's priced for "perfect."

Four consecutive quarters of earnings beats had built an expectation structure where anything short of a clean sweep was treated as failure. A 1% revenue miss at that multiple triggers a systematic de-risking: quantitative funds reduce exposure, growth-focused institutions trim positions, and momentum sellers pile on. The result is a 20% drawdown that looks disproportionate to the fundamental reality.

The Guidance Problem: Why Q3 Mattered More Than Q2

The real issue for AppLovin wasn't the Q2 miss — it was the Q3 guidance. At $2.07B, APP's forward guidance came in 0.6% below the Street's consensus. That's a small miss on an absolute basis, but it signals something the market was hoping it wouldn't hear: that APP's exceptional growth trajectory is starting to encounter friction.

App advertising is a cyclical business with seasonal patterns, and Q3 typically sees some advertising budget reallocation. APP had been overcoming those headwinds through its Axon algorithm improvements. If the algorithm's edge is showing diminishing marginal returns — even slightly — at this valuation, the risk-reward calculus changes meaningfully.

This doesn't mean AppLovin is broken. A 53% revenue growth rate with 84% EBITDA margins is still elite. But the premium multiple requires premium execution, every single quarter. That streak ended Wednesday night.

The Divergence Lesson: Expectations Are the Asset

The LLY/APP divergence captures a core truth about equity markets that no amount of DCF modeling can fully quantify: what a stock price reflects about the future is more important than what a company actually did in the past quarter.

Lilly was priced for "good pharmaceutical execution" and delivered "unprecedented pharmaceutical execution." The gap between expectation and reality was vast and positive. The stock rose 4%.

AppLovin was priced for "continued perfection" and delivered "excellent, but slightly imperfect execution." The gap between expectation and reality was tiny and negative. The stock fell 20%.

This asymmetry is not irrational — it's actually the market functioning correctly. Price is a forward-looking mechanism. When APP was trading at its premium multiple, that multiple was pricing in a specific future. When that future showed the first crack, the repricing was swift and significant.

What to Watch Next

  • LLY supply expansion: Lilly's next constraint is manufacturing capacity. Watch for updates on their Indiana and Ireland facilities — if they can keep pace with demand growth, the GLP-1 story has further room to run.
  • APP at the dip: For long-term investors, a 20% haircut on a structurally sound adtech business with 53% growth is worth re-evaluating. The question is whether the Q3 guidance miss represents a temporary air pocket or a trend break.
  • Pharma vs. Tech rotation: This earnings season has featured repeated instances of biotech/pharma delivering while consumer-facing tech disappoints. If that pattern holds through the rest of August, sector rotation could accelerate.
  • S&P 500 at 7,723: The index closed Aug 6 at 7,723 — a slight pullback from the 7,842 ATH hit on Aug 5. The healthy digestion continues. First real support: 7,620.

The Schwartz is strong with Lilly. The Schwartz is asking AppLovin to recalibrate. May the Force — and your position sizing — be with you. 🧘‍♂️✨